Skip to main content
. Author manuscript; available in PMC: 2023 Nov 1.
Published in final edited form as: Psychopharmacology (Berl). 2022 Sep 13;239(11):3539–3550. doi: 10.1007/s00213-022-06226-1

Figure 3. EGR3 overexpression in the mPFC increase the rewarding effects of oxycodone.

Figure 3.

(a) Experimental timeline for EGR3 overexpression in the mPFC followed by oxycodone self-administration and progressive ratio behavior. Numbers of infusions (b, c) and breakpoints (d) in a 6-h progressive ratio test in rats microinjected with AAV-GFP or AAV-EGR3. * represents significant differences between AAV-GFP and AAV-EGR3 in number of infusion and breakpoint. All data are presented as means ± SEMs with statistical significance (*) at P < 0.05.